UCB cuts price, extends €1bn revolver

Belgian pharmaceutical firm UCB has become the latest western European firm to reduce the cost of its bank debt, after closing an amend-and-extend agreement on a €1bn revolving credit facility.

  • By Michael Turner
  • 20 Jan 2014
The maturity of the facility has been moved from 2016 to 2019, with two one year extension options. 

UCB is paying less for the new loan than it was for the existing deal, according to the company.

The borrower began speaking to its core relationship banks at the end of ...

Please take a trial or subscribe to access this content.

Contact Mark Goodes to discuss your access: mark.goodes@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Share % by Volume
1 Societe Generale 15.35
2 Rabobank 14.41
3 Morgan Stanley 11.73
4 Barclays 8.99
5 Credit Agricole 7.57

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 27 Feb 2017
1 Wells Fargo Securities 11,897.40 33 11.83%
2 Bank of America Merrill Lynch 9,837.56 29 9.78%
3 Citi 9,714.54 32 9.66%
4 JPMorgan 7,997.38 24 7.95%
5 Credit Suisse 6,335.67 14 6.30%